Difference between revisions of "Malignant solid neoplasm, EGFR-mutated"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "'''contains verified protocol'''" to "'''contains dosing details in manuscript'''") |
m |
||
| Line 9: | Line 9: | ||
|} | |} | ||
{{TOC limit|limit=3}} | {{TOC limit|limit=3}} | ||
| − | |||
=All lines of therapy= | =All lines of therapy= | ||
==Erlotinib monotherapy {{#subobject:e0d17a|Regimen=1}}== | ==Erlotinib monotherapy {{#subobject:e0d17a|Regimen=1}}== | ||
| + | <div class="toccolours" style="background-color:#eeeeee"> | ||
===Regimen {{#subobject:392a4b|Variant=1}}=== | ===Regimen {{#subobject:392a4b|Variant=1}}=== | ||
| − | {| class="wikitable" style="width: | + | {| class="wikitable sortable" style="width: 60%; text-align:center;" |
| − | !style="width: | + | !style="width: 33%"|Study |
| − | !style="width: | + | !style="width: 33%"|Years of enrollment |
| + | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
|[https://doi.org/10.1200/JCO.2017.75.3780 Hainsworth et al. 2018 (MyPathway)] | |[https://doi.org/10.1200/JCO.2017.75.3780 Hainsworth et al. 2018 (MyPathway)] | ||
| + | |2014-2016 | ||
|style="background-color:#ffffbe"|Phase 2a, <20 pts in this arm | |style="background-color:#ffffbe"|Phase 2a, <20 pts in this arm | ||
|- | |- | ||
|} | |} | ||
| + | <div class="toccolours" style="background-color:#fdcdac"> | ||
====Biomarker eligibility criteria==== | ====Biomarker eligibility criteria==== | ||
*Gene: EGFR | *Gene: EGFR | ||
| Line 26: | Line 29: | ||
*Acceptable methods of measurement: molecular profiling performed on tissue obtained at the most recent tumor biopsy | *Acceptable methods of measurement: molecular profiling performed on tissue obtained at the most recent tumor biopsy | ||
*Biomarker exclusions: EGFR exon 20 [[Biomarkers#SNV|mutations]] | *Biomarker exclusions: EGFR exon 20 [[Biomarkers#SNV|mutations]] | ||
| + | </div> | ||
| + | <div class="toccolours" style="background-color:#b3e2cd"> | ||
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Erlotinib (Tarceva)]] 150 mg PO once per day | *[[Erlotinib (Tarceva)]] 150 mg PO once per day | ||
| − | |||
'''Continued indefinitely''' | '''Continued indefinitely''' | ||
| − | + | </div></div> | |
===References=== | ===References=== | ||
# '''MyPathway:''' Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study. J Clin Oncol. 2018 Feb 20;36(6):536-542. Epub 2018 Jan 10. [https://doi.org/10.1200/JCO.2017.75.3780 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/29320312 PubMed] NCT02091141 | # '''MyPathway:''' Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study. J Clin Oncol. 2018 Feb 20;36(6):536-542. Epub 2018 Jan 10. [https://doi.org/10.1200/JCO.2017.75.3780 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/29320312 PubMed] NCT02091141 | ||
| − | |||
[[Category:EGFR regimens]] | [[Category:EGFR regimens]] | ||
[[Category:Biomarker-specific pages]] | [[Category:Biomarker-specific pages]] | ||
[[Category:Malignant solid neoplasm]] | [[Category:Malignant solid neoplasm]] | ||
[[Category:Site-agnostic regimens]] | [[Category:Site-agnostic regimens]] | ||
Revision as of 13:08, 23 January 2023
1 regimens on this page
1 variants on this page
|
All lines of therapy
Erlotinib monotherapy
Regimen
| Study | Years of enrollment | Evidence |
|---|---|---|
| Hainsworth et al. 2018 (MyPathway) | 2014-2016 | Phase 2a, <20 pts in this arm |
Biomarker eligibility criteria
References
- MyPathway: Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study. J Clin Oncol. 2018 Feb 20;36(6):536-542. Epub 2018 Jan 10. link to original article contains dosing details in manuscript PubMed NCT02091141